TrialLeukemia2020

ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Denis Claude Roy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.